Lamprene (Clofazimine)

Clofazimine intercalates into bacterial DNA, disrupting replication, and generates reactive oxygen species through redox cycling that damage mycobacterial cell membranes. It also accumulates in macrophages, providing sustained activity against dormant bacilli, and exerts anti‑inflammatory effects that help control leprosy reactions.

The specific dose of Lamprene is determined by the prescribing clinician based on the patient’s condition, weight, and treatment guidelines. Dosage regimens may vary, and adjustments are made for renal or hepatic impairment as needed.

Safety of Clofazimine in pregnancy and lactation has not been established. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus, and breastfeeding is generally discouraged unless the infant is closely monitored for skin discoloration or other effects.

To order Lamprene, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for leprosy treatment is the multidrug regimen that includes dapsone and rifampicin. Compared with dapsone, Clofazimine has a distinct mechanism involving DNA intercalation and reactive oxygen species generation, and it offers additional anti‑inflammatory benefits, though it is more associated with skin pigmentation changes.

Lamprene capsules should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in a refrigerator or freezer, and keep out of reach of children.

Lamprene is taken orally as a 100 mg capsule. It can be swallowed whole with a glass of water, with or without food, as directed by the prescriber. Consistency in timing helps maintain steady drug levels.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, significant hepatotoxicity, and hematologic abnormalities like neutropenia or eosinophilia. Patients should report any unexplained rash, yellowing of the skin or eyes, or unusual bruising promptly.

Lamprene should be avoided in individuals with known hypersensitivity to Clofazimine or any phenazine dyes. Patients with severe liver disease or uncontrolled hepatic impairment should not use it without close monitoring. Caution is also advised for those with pre‑existing cardiac conditions that predispose to QT prolongation.